By Ana Espino | Published on August 19, 2025 | 2 min read
#Influenza #Bronchiectasis
Bronchiectasis is a chronic lung
disease characterized by
irreversible dilation of the bronchi, leading to
mucus
accumulation, persistent inflammation, and
increased susceptibility to
respiratory infections. Despite therapeutic advances, management remains
limited by the challenge of controlling chronic inflammation and preventing
frequent exacerbations. Recent evidence suggests an
infectious etiology in the
development and progression of the disease, underscoring the importance of
microbial agents in its evolution.
A
major challenge therefore lies in
identifying infectious agents that fuel the vicious cycle of
inflammation–infection–tissue damage, in order to better target clinical
management.
Haemophilus influenzae (H. influenzae), a bacterium
frequently isolated in these patients, raises questions about its exact
pathogenic role—whether it acts as a mere colonizer or as a central driver of
disease progression. This study was initiated to analyze the impact of H. influenzae
on pathophysiology, exacerbations, immune response, and prognosis in patients
with bronchiectasis.
H. influenzae, the prime suspect?
This review is based on clinical and microbiological studies of patient cohorts
with bronchiectasis. The studies assessed the frequency of H. influenzae
isolation in sputum and bronchial samples. Host response—particularly
neutrophilic inflammation and the production of pro-inflammatory cytokines—was
observed. Several longitudinal studies were included to establish a link
between chronic colonization by H. influenzae, exacerbation frequency, and
decline in lung function.
Findings show that
H. influenzae is
one of the most frequently isolated pathogens, often detected chronically. Its
presence is associated with
persistent neutrophilic inflammation, increased
production of pro-inflammatory cytokines, and
worsening bronchial remodeling.
Several studies demonstrate that colonized patients face a
higher risk of
exacerbations, reduced lung function, and
poorer quality of life.
Immunologically, chronic infection with H. influenzae is accompanied by an
insufficient antibody response, suggesting the host’s inability to eradicate
the bacterium effectively. Culture and molecular biology studies also confirm
substantial genetic variability among strains, complicating treatment and
promoting persistence.
Toward targeted management?
Bronchiectasis remains a burdensome chronic condition, sustained by a vicious
cycle of infection and inflammation. Available data show that H. influenzae
plays a central role in symptom worsening and increased exacerbation risk,
making it a potential therapeutic and diagnostic target. The aim of this review
was to clarify its involvement in the disease and guide research toward more
targeted strategies. While evidence supports its active role, limitations
include the difficulty of distinguishing colonization from infection,
heterogeneity among studies, and a lack of longitudinal data.
Future research should
identify
specific biomarkers, improve antibiotic strategies, explore new vaccine
approaches, and develop
personalized protocols to better control the impact of
H. influenzae on the progression of bronchiectasis.
Read next: CD146: friend or foe of the lung?
About the author – Ana EspinoPhD in Immunology, specialized in Virology
